PALO ALTO, Calif. / Aug 28, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team.
Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com. Due to limited capacity, in-person attendance is available by invitation only.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
| Last Trade: | US$99.20 |
| Daily Change: | 6.18 6.64 |
| Daily Volume: | 1,998,909 |
| Market Cap: | US$12.370B |
October 29, 2025 October 27, 2025 October 26, 2025 October 15, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
